Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 110Terminated 26Recruiting 24Active not recruiting 21Unknown 15Withdrawn 9Not yet recruiting 4Suspended 1

Sponsor Class

OTHER 2NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 30Breast 18Other hematologic neoplasm 15Plasma cell 8CNS 6Sarcoma 4Head & Neck 4Genitourinary 4Thoracic 3Gastrointestinal 3Other solid neoplasm 2Gynecologic 2Dermatologic 1

Conditions

Dendritic Cell Sarcoma, Interdigitating 2Triple Negative Breast Neoplasms 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Carcinoma, Renal Cell 1

Interventions

Doxorubicin 5Cyclophosphamide 4Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2anlotinib 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1relmacabtagene autoleucel 1regorafenib 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1irinotecan sucrosofate 1fludarabine 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Cyclophosphamide × Sarcoma × Clear all
NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canadian Cancer Trials Group

Phase 1 Not yet recruiting
30 enrolled
BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 2 Not yet recruiting
40 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
134 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡